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Abstract
Aim This study investigates the relationship between basal insulin regimen and glycaemic outcomes 12 months after
skills-based structured education in the UK Dose Adjustment for Normal Eating (DAFNE) programme for Type 1
diabetes mellitus.
Method Retrospective analysis of data from 892 DAFNE participants from 11 UK centres.
Results Mean HbA1c 12 months after DAFNE was lower in those using twice- rather than once-daily basal insulin after
correcting for differences in baseline HbA1c, age and duration of diabetes; difference –2 (95% CI –3 to –1) mmol/mol
[–0.2 (–0.3 to –0.1)%], P = 0.009. The greatest fall in HbA1c of –5 (–7 to –3) mmol/mol [–0.4 (–0.6 to –0.3)%],
P < 0.001 occurred in those with less good baseline control, HbA1c ≥ 58 mmol/mol, who switched from once- to twice-
daily basal insulin. There was no difference in the 12-month HbA1c between users of glargine, detemir and NPH insulin
after correcting for other variables. Relative risk of severe hypoglycaemia fell by 76% and ketoacidosis by 63%
12 months after DAFNE. The rate of severe hypoglycaemia fell from 0.82 to 0.23 events/patient year in twice-daily
basal insulin users. In the group with greatest fall in HbA1c, the estimated relative risk for severe hypoglycaemia in twice-
daily basal insulin users versus once daily at 12 months was 1.72 (0.88–3.36, P = 0.110).
Conclusion After structured education in adults with Type 1 diabetes mellitus, use of basal insulin twice rather than
once daily was associated with lower HbA1c, independent of insulin type, with significant reductions in severe
hypoglycaemia and ketoacidosis in all groups.
Diabet. Med. 32, 1071–1076 (2015)
Introduction
The Dose Adjustment for Normal Eating (DAFNE) pro-
gramme provides structured education in flexible intensive
insulin therapy for adults with Type 1 diabetes mellitus both
within and beyond the UK [1]. Emphasis is placed on
carbohydrate counting and meal-related short-acting insulin
dose adjustment. Education and skills-based training on how
to adjust basal insulin doses are also key components in the
curriculum, but may be seen by users as having a secondary
role [2]. DAFNE is based on the original German ITT course
[3] and its efficacy has been demonstrated in a randomized
controlled trial in which participants used exclusively twice-
daily (bd) NPH as basal insulin [4]. However, long-acting
insulin analogues are now frequently prescribed and are
often injected once (od) rather than twice daily. There is little
evidence on whether the type or frequency of injection of
basal insulin influences glycaemic control after structured
education. This study investigates the relationship between
basal insulin regimen and glycaemic outcomes 12 months
after DAFNE training.
Methods
We collected baseline and 12-month follow-up data for
patients who had completed DAFNE training from the
DAFNE research database from its inception in 2009 to
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2012, and also information for 2007 to 2012 from the
Glasgow DAFNE service, which does not participate in the
research database. All patients undertook DAFNE training as
part of their routine clinical care. Course participants are
initially encouraged to adopt a basal regimen of 12 units twice
daily unless clinical features suggest otherwise. They are
taught how to self-adjust basal insulin by making 1–2 unit
changes in dose every 2–3 days to achieve fasting glucose
targets, with specific rules for overnight hypoglycaemia.
Occasional glucose testing at 3 a.m. and after carbohydrate-
free meals is promoted to check the basal insulin dose(s), and
patients are given additional algorithms for self-adjustment in
relation to exercise and illness. They also evaluate their own
insulin sensitivity to facilitate calculation of carbohydrate-
related prandial insulin and correction doses. Regular capil-
lary glucosemeasurements are recommendedbeforemeals and
before bed with additional tests for management of exercise,
hypoglycaemia and driving. The course lasts 5 days. There is a
robust quality assurance process to ensure consistency in
course delivery between centres [5]. Severe hypoglycaemia is
routinely documented at baseline and 12 months by interview
and questionnaire, based on patient recall.
Ten UK centres contribute to the research database, which
holds demographic data (gender, age and duration of
diabetes), Diabetes Control and Complications Trial
(DCCT)-aligned HbA1c, type and frequency of basal insulin
injection and patient-reported numbers of episodes of severe
hypoglycaemia (defined as requiring third party assistance)
and ketoacidosis in the 12 months before DAFNE and in the
12 months thereafter. Matching data for the Glasgow service
were gathered from the DAFNE clinical audit database; and
the Scottish Care Information–Diabetes Care system (SCI-
DC, now SCI-Diabetes) for type and frequency of basal
insulin injection. Paper clinical records were used where data
could not otherwise be obtained.
Exclusion criteria were pregnancy or continuous subcuta-
neous insulin infusion use at baseline or 12 months; missing
HbA1c, basal insulin type or frequency at baseline or
12 months; and use of basal insulin other than once or twice
daily. Analyses were performed for the whole cohort, and on a
reduced cohort comprising patients with baseline
HbA1c ≥ 58 mmol/mol (≥ 7.5%, an inclusion criterion in the
DAFNERCT) [4]. HbA1c ≥ 58 mmol/mol (≥ 7.5%) identifies
participants in whom improving glycaemic control is likely to
be a prime objective of structured education additional to
improving quality of life with diabetes. Data for severe
hypoglycaemia were also analysed separately for those with
HbA1c < 58 mmol/mol (< 7.5%) at baseline, as those with
lower values alreadymayhavemore incentive to use structured
education to reduce their future risk of hypoglycaemia [6].
Glycaemic outcomes were assessed in relation to frequency of
basal insulin injection and type using a linear multiple
regression model for HbA1c. Negative binomial models and
logistic regression modelling were used to analyse patterns in
severe hypoglycaemia and ketoacidosis data. All models used
population-averaged exchangeable correlation and robust
standard errors to allow for clustering by centre. Analyses
were performed using IBM SPSS Statistics for Windows,
v. 21.0 (Armonk USA) and figures were drawn using R [7].
Results
Of 1238 patients with 12-month data, 99 were excluded
because of pregnancy or continuous subcutaneous insulin
infusion use. There were 892 (78.3%) eligible patients with
complete data. Mean (SD) age was 41.1 (13.6) years, duration
of diabetes 18.9 (13.4) years; 47%were men. Baseline HbA1c
was ≥ 58 mmol/mol (≥ 7.5%) in 739 (82.8%) patients.
At baseline, 3.8% of patients were using pre-mixed insulin,
31.6% basal insulin detemir (od 13.8%, bd 17.8%), 48%
basal insulin glargine (od 42.4%, bd 5.6%) and 16.6% NPH
(od 6.7%, bd 9.9%). At 12 months, basal insulin usage was
detemir 40.2% (od 8.6%, bd 31.6%), glargine 42.0% (od
30.3%, bd 11.7%) and NPH 17.8% (od 1.6%, bd 16.2%).
The pattern of basal insulin use for the reduced cohort both
at baseline and at 12 months varied by < 1% from the
above. Excluding those using mixed insulin, before DAFNE
65.4% (561/858) were using once-daily basal insulin. This
decreased to 40.8% (350/858) after DAFNE (difference –
24.6%, 95% CI: –27.7% to –21.5%, P < 0.001).
HbA1c
There was a fall in HbA1c for the whole cohort of –2 (95%
CI –3 to –1) mmol/mol [–0.2 (–0.3 to –0.1)%], P < 0.001.
Those using twice-daily basal insulin at 12 months had a
greater fall in HbA1c of –3 (–4 to –2) mmol/mol [–0.3 (–0.4
to –0.2)%], P < 0.001, whereas those using once-daily basal
insulin showed no significant fall; difference –1 (–2 to –1)
What’s new?
• In people with Type 1 diabetes mellitus a once-daily
basal insulin regimen is sometimes used instead of the
evidence-based twice-daily regimen during structured
education.
• This retrospective study demonstrates lower HbA1c in
twice-daily basal insulin users after Dose Adjustment
for Normal Eating (DAFNE) education.
• Benefit in reduced severe hypoglycaemia and ketoaci-
dosis is not influenced by basal insulin frequency or
type.
• Consistency of mealtime insulin replacement and basal
insulin dose-adjustment training may allow differences
to be detected in this study in contrast to recent reports
showing no effect of basal insulin frequency on HbA1c.
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mmol/mol [–0.1 (–0.2 to –0.1)%], P = 0.222. For the
reduced cohort with less good control at baseline, there
was a fall in HbA1c at 12 months of –4 (–4 to –3) mmol/mol
[–0.3 (–0.4 to –0.2)%], P < 0.001; a fall of –5 (–7 to –
3) mmol/mol [–0.4 (–0.5 to –0.3)%] in the subgroup using
basal insulin twice daily, P < 0.001; and a fall of –2 (–3 to
0) mmol/mol [–0.2 (–0.3 to –0.1)%], P = 0.011 in the group
using basal insulin once daily (Fig. 1).
Table 1 showsdata frompatients groupedaccording to their
pattern of basal insulin injection at baseline and 12 months.
Excluding baseline mixed insulin users, in the whole cohort,
those that switched fromonce- to twice-dailybasal insulin (od–
bd) had a change inHbA1c of –3 (–5 to –2) mmol/mol [–0.3 (–
0.4 to –0.2)%], P < 0.001, and in the group using twice-daily
basal insulin both at baseline and12 months (bd–bd) of –3 (–4
to –1) mmol/mol [–0.3 (–0.4 to –0.1)%],P < 0.001; therewas
no significant change in theHbA1c in the groupwho continued
to use once-daily basal insulin (od–od), or in the small number
of patients who changed from twice-daily to once-daily basal
insulin (bd–od) (Table 1). The same pattern was found in the
data for the reduced cohort with the greatest fall in HbA1c of –
5 (–7 to –3) mmol/mol; [–0.4 (–0.6 to –0.3)%], P < 0.001 in
the od-bd group.
Change in HbA1c correcting for age, duration of diabetes and
baseline HbA1c
The linear modelling analysis showed no difference in 12-
month HbA1c between the three types of basal insulin, NPH,
levemir and glargine, in the whole (P = 0.281) or reduced
(P = 0.337) cohorts. However, the group using twice-daily
basal insulin had a lower HbA1c at 12 months than those
using once daily both in the whole cohort; 69 vs. 71 mmol/
mol (8.4% vs. 8.6%), difference –2 mmol/mol, 95% CI: –3
to –1 [–0.2 (–0.3 to –0.1)%], P = 0.009 and in the reduced
cohort; 71 vs. 74 mmol/mol (8.7% vs. 8.9%); difference –
3 (–4 to –1) mmol/mol [–0.2(–0.4 to –0.1)%], P = 0.006.
Excluding those using mixed insulin at baseline, linear
modelling using the grouping according to pattern of basal
insulin use showed an overall difference between groups at
12 months (P = 0.001). Post-hoc comparisons in the full
cohort showed lower 12-month HbA1c in the od–bd group
than the od–od group; difference –2 (95% CI –4 to –
1) mmol/mol [–0.2 (–0.3 to –0.1)%], P < 0.001, and in the
bd–bd group compared with the od–od group; difference –
2 (–4 to –1) mmol/mol [–0.2 (–0.4 to –0.1)%], P = 0.005.
The same analyses performed in the reduced cohort showed
difference: –3 (–6 to –1) mmol/mol [–0.3(–0.5 to –0.1)%],
P = 0.001 and difference: –3 (–5 to –1) mmol/mol [–0.3
(–0.5 to –0.1)%], P = 0.001, respectively.
Severe hypoglycaemia
Data on severe hypoglycaemia in the 12 months before and
after DAFNE were available for 730 patients (81.8%) in the
full cohort (Table 2) and 596 (80.1%) in the reduced cohort.
Rate of severe hypoglycaemia fell from 0.85 to 0.20 episodes
per patient per year in the full cohort, estimated relative risk
FIGURE 1 Mean HbA1c at baseline and 12 months after structured education in DAFNE shown for the reduced cohort (baseline HbA1c ≥ 58 mmol/
mol, ≥ 7.5%) and subgroups of participants analysed according to basal insulin regimen at 12 months, with 95% confidence intervals and P values
derived from paired t-tests. The 12-month HbA1c is significantly lower than baseline in all subgroups.
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0.24 (95% CI: 0.16–0.36, P < 0.001); from 0.83 to 0.20
episodes per patient per year in the reduced cohort, with
relative risk 0.26 (95% CI: 0.16–0.40, P < 0.001). In the full
cohort, the rate of severe hypoglycaemia in twice-daily basal
insulin users fell from 0.89 to 0.23, and from 0.82 to 0.15 in
once-daily users. The estimated odds ratio (OR) of severe
hypoglycaemia afterDAFNE compared to beforeDAFNEwas
0.32 (95% CI: 0.27–0.38, P < 0.001) in the full cohort and
0.33 (95% CI: 0.26–0.42, P < 0.001) in the reduced cohort.
For patients who entered DAFNE with good glycaemic
control [baseline HbA1c < 58 mmol/mol (7.5%), n = 134]
there was no significant difference in severe hypoglycaemia at
12 months between once and twice-daily basal insulin users.
A negative binomial model was used to test for a difference
in the rate of severe hypoglycaemia at 12 months between
different types of basal insulin and frequency of basal insulin
injection, adjusted for the number of severe hypoglycaemia
events at baseline, HbA1c at 12 months, age and diabetes
duration. This found no overall difference between 12-month
severe hypoglycaemia rates for the three types of insulin (full
cohort P = 0.389; reduced cohort P = 0.298). The estimated
relative risk of severe hypoglycaemia for those using twice-
daily compared with once-daily basal insulin was 1.85 (95%
CI: 1.01–3.42, P = 0.049); in the reduced cohort with poorer
baseline control 1.72 (95% CI: 0.88–3.36, P = 0.110); and
in the small group with good baseline control 3.86 (95% CI:
0.55–24.88, P = 0.181).
A logistic regression model was used to test if there was a
difference in the number of people having at least one severe
hypoglycaemia event at 12 months between the different
types of insulin and the number of injections. This model was
adjusted for HbA1c at 12 months, age, duration and if the
Table 1 Whole-cohort HbA1c data: participants grouped by frequency of basal insulin injection at baseline and 12 months. There was a significant
fall in HbA1c for twice-daily basal insulin users who continue to use twice daily, and in once-daily basal insulin users who switch to twice daily after
structured education in DAFNE
Group
Baseline
basal
insulin
regimen
12-month
basal insulin
regimen N
Baseline HbA1c
mmol/mol (%)
12-month HbA1c
mmol/mol (%)
Difference
between
baseline and
12-month HbA1c
mmol/mol (%) 95% CI PMean SD Mean SD
1 Once daily Once daily 341 72 (8.8) 17 (1.5) 71 (8.8) 17 (1.5) –1 (–0.1) –2 to 1 (–0.2 to 0.1) 0.281
2 Once daily Twice daily 220 71 (8.8) 14 (1.3) 68 (8.5) 14 (1.3) –3 (–0.3) –5 to –2 (–0.4 to –0.2) < 0.001
3 Twice daily Once daily 9 81 (9.7) 23 (2.1) 77 (9.3) 17 (1.5) –4 (–0.4) –17 to 8 (–1.5 to 0.7) 0.449
4 Twice daily Twice daily 288 71 (8.8) 15 (1.4) 69 (8.5) 15 (1.4) –3 (–0.3) –4 to –1 (–0.4 to –0.1) < 0.001
Table 2 Event data for the full cohort for severe hypoglycaemia (n = 730) and diabetic ketoacidosis (n = 689) at baseline and 12 months after
skills-based training in DAFNE
Before DAFNE training (baseline) 12 months after DAFNE training
Patients Events Range Rate* %† Patients Events Range Rate* %†
Severe hypoglycaemia
Injections
Once daily 455 375 0–40 0.82 20.9 284 42 0–12 0.15 6.7
Twice daily 275 244 0–50 0.89 23.3 446 102 0–12 0.23 9.2
Insulin type
NPH 138 72 0–8 0.52 21.0 142 22 0–6 0.15 5.6
Glargine 342 375 0–50 1.10 21.3 300 75 0–12 0.25 9.3
Detemir 227 154 0–20 0.68 22.5 288 47 0–12 0.16 8.3
Mixed 23 18 0–8 0.78 26.1 – – – – –
Total 730 619 0–50 0.85 21.8 730 144 0–12 0.20 8.2
Ketoacidosis
Injections
Once daily 434 31 0–3 0.07 4.8 272 8 0–1 0.03 2.9
Twice daily 255 13 0–3 0.05 4.3 417 8 0–2 0.02 1.7
Insulin type
NPH 116 9 0–2 0.08 6.9 121 2 0–1 0.02 1.7
Glargine 337 25 0–3 0.07 5.0 295 9 0–1 0.03 3.1
Detemir 214 8 0–3 0.04 2.3 273 5 0–2 0.02 1.5
Mixed 22 2 0–1 0.09 9.1 – – – – –
Total 689 44 0–3 0.06 4.6 689 16 0–2 0.02 2.2
*Number of events per patient per year.
†Per cent of patients with at least one event.
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individual had severe hypoglycaemia at baseline or not. The
estimated OR for severe hypoglycaemia of those using twice-
daily basal insulin compared with those using once-daily
basal insulin in the full cohort was 2.68 (95% CI: 1.29–3.52,
P = 0.003) and in the reduced cohort 1.80 (1.02–3.16,
P = 0.041).
In the full cohort, the estimated OR for severe hypoglyca-
emia between basal insulin pairs were glargine : NPH 2.68
(95% CI: 1.38–5.21, P = 0.004), detemir : NPH 1.57 (95%
CI: 0.64–3.81, P = 0.323) and glargine : detemir 1.71 (95%
CI: 0.97–3.01, P = 0.062); respective ratios in the reduced
cohort were 2.81 (95% CI: 1.14–6.95, P = 0.025), 1.28
(95% CI: 0.46–3.53, P = 0.637) and 2.20 (95% CI: 1.18–
4.12, P = 0.014).
Modelling analyses using the grouping according to
pattern of basal insulin use (Table 1) showed no difference
in estimated relative risk or in OR for severe hypoglycaemia
between groups 1 to 4.
Diabetic ketoacidosis
Ketoacidosis data were available for 689 patients (77.2%) in
the full cohort (Table 2) and 577 (78.1%) in the reduced
cohort. Absolute numbers of episodes were small; 44 at
baseline and 16 at 12 months. In the full cohort, rates of
ketoacidosis fell from 0.06 to 0.02 episodes per patient per
year, estimated relative risk 0.37 (95% CI: 0.20–0.68,
P = 0.001), and in the reduced cohort from 0.07 to 0.02
episodes per patient per year, relative risk 0.37 (95% CI:
0.18–0.72, P = 0.004). The estimated OR of ketoacidosis
after DAFNE compared with before DAFNE in the full
cohort was 0.46 (95% CI: 0.27–0.76, P = 0.002) and in the
reduced cohort was 0.44 (95% CI: 0.25–0.76, P = 0.003).
In the negative binomial model comparing the rates of
ketoacidosis at 12 months, adjusting for the number of ketoac-
idosis episodes at baseline, HbA1c at 12 months, age and
duration of diabetes, there was no difference in the estimated
relative risk of ketoacidosis for those using twice- compared
with once-daily basal insulin: full cohort 1.26 (95% CI: 0.44–
3.59, P = 0.665); reduced cohort 1.22 (95% CI: 0.39–3.78,
P = 0.734). In the logistic regression model testing for a
difference in the number of people having at least one
ketoacidosis episode at 12 months between the different types
of basal insulin and the number of injections, adjustment was
made for HbA1c at 12 months, age, duration and if the
individual had a ketoacidosis episode at baseline or not. There
was no difference in the estimated OR ratio for diabetic
ketoacidosis in twice-daily basal insulin users compared to once
daily: full cohort 1.20 (95% CI: 0.41 to 3.56, P = 0.739;
reduced cohort P = 0.808). There is an overall difference in
number of people having at least one ketoacidosis episode at
12 months between the different types of basal insulin: full
cohort P = 0.004; reduced cohort P = 0.025. We have not
investigated for differences in ketoacidosis rates between
individualbasal insulinsdue to the lowtotalnumberofepisodes.
Modelling analyses using the grouping according to
pattern of basal insulin use (Table 1) showed no difference
in estimated relative risk or in OR for ketoacidosis between
groups 1 to 4.
Discussion
This analysis of clinical audit data from UK DAFNE services
has shown an increased HbA1c benefit from twice- rather than
once-daily usage of basal insulin 12 months after DAFNE
training in insulin self-management skills for Type 1 diabetes
mellitus. The most clinically meaningful fall in HbA1c of
5 mmol/mol (0.4%) was associated with patients who
embarked on DAFNE with higher baseline HbA1c ≥
58 mmol/mol (7.5%) and were using the recommended
twice-daily basal insulin regimen after DAFNE. By contrast,
the North American Type 1 Diabetes Exchange Clinic Regis-
try have published data in abstract form without finding any
difference in outcomes between once-daily and twice-daily
basal insulin users [8]. A recent systematic review and network
meta-analysis [9] examined both randomized and non-
randomized studies comparing basal insulin regimens in
people with Type 1 diabetes mellitus. The analysis was
primarily designed to consider differences between insulin
types, but studies using one insulin type at different injection
frequencies were also included. This analysis also found no
systematic differences inHbA1c between once- and twice-daily
basal insulin use for any ofNPH, detemir or glargine. The data
used in these analyses are from a variety of centres with no
unifying educational curriculum and so differ markedly from
our study population of people who have received uniform
guidance for dose adjustment. We may, therefore, be able to
detect differences relating to the insulin regimen because of
consistency both in themeal-related insulin replacement and in
basal insulin dose-adjustment behaviours; and outcomes may
relate to the difference between randomized trials and partic-
ipant preference for once- or twice-daily basal insulin use. In
clinical practice, patients embark on DAFNE training with a
variety of issues including HbA1c above target, problematic
hypoglycaemia and a desire for dietary freedom. Our study
does not allow us to explain the rationale behind choices of
basal insulin regimen.
One possible reason for clinicians recommending analogue
basal insulin over NPH may be concern over hypoglycaemia.
These data confirm earlier reports of a major reduction in
severe hypoglycaemia 12 months after the ITTP and DAFNE
[6,10,11], which is largely independent of HbA1c (above or
below 58 mmol/mol, 7.5%), insulin type or injection fre-
quency. We propose the 76% reduced risk of severe
hypoglycaemia arises from the total DAFNE education
package, not just the basal insulin regimen. The statistical
modelling corrects for baseline hypoglycaemia events as well
as HbA1c, both of which can be linked to future severe
hypoglycaemia risk. For participants with baseline
HbA1c ≥ 58 mmol/mol (7.5%) using twice-daily basal
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insulin at 12 months the fall in mean HbA1c of 5 mmol/mol
(0.4%) could provide a ~ 15% reduction in estimated risk of
microvascular complications. Although the estimated relative
risk of severe hypoglycaemia in this group compared with the
once-daily users was 1.72 (OR 1.8), given the large fall in
absolute risk of hypoglycaemia after DAFNE, this equates to
a difference in absolute risk of one severe hypoglycaemic
episode every 14 months reducing to one every 3 years in
twice daily users vs. one every 13 months reducing to one
every 5 years in once-daily basal insulin users. There is
evidence that severe hypoglycaemic events are recalled
accurately by users at 12 months [12] and more than 90%
of participants in this study were event-free at 12 months.
The reduced rate of ketoacidosis seen in all groups is also
likely to be related to DAFNE self-management education
in toto rather than basal insulin regimen. There were differ-
ences between the modelling results comparing severe hypo-
glycaemia betweenbasal insulin typeswith a tendency towards
more events in glargine users compared with NPH and
detemir. Our data do not allow us to examine behaviours
such as exercise and adherence to self-monitoring, or partic-
ipants’ or professionals’ preferences for different basal regi-
mens. One possible explanation is reverse causation, with
clinicians prescribing glargine and promoting twice-daily
basal insulin regimens in peoplemost prone to hypoglycaemia.
Analogue basal insulin has been reported to be associated
with more reproducible action profiles than NPH [13],
although this has not been tested for clinical impact in
patients with advanced insulin self-management skills. In the
current study, there was no significant difference between the
HbA1c at 12 months for users of different basal insulin types,
suggesting that any biological variability between insulin
types may not be clinically relevant in this setting. High-
quality skills-based structured education is a more powerful
intervention for the outcomes considered here than the
influence of basal insulin type.
The mechanisms by which a twice-daily basal insulin
regimen is associated with improved HbA1c at 12 months
compared with once daily cannot be established in a study of
this type. Our data are retrospective and on-going research
into optimum basal insulin regimens is required.
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